(Total Views: 188)
Posted On: 03/17/2022 4:04:34 PM
Post# of 1354
NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Issues Update on Key 2022 Goals and Milestones, Planned Uplist to National Exchange
Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and specialty services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food and beverage industries, today updated stakeholders on the company’s key 2022 goals. PBI believes these goals are attainable in the current fiscal year and that their achievement will put the company on a rapid path to sustained growth, value increase and profitability. “In addition to the record number of instrument orders for a month, interest and engagement with our enabling BaroFold Platform protein refolding services has grown significantly over the past few months,” said Richard T. Schumacher, president and CEO of PBI. “We have also made measurable progress thus far in Q1 2022 in preparing for the commercialization of our revolutionary Ultra Shear Technology(TM) (‘UST(TM)’) Platform. Of particular note, we have significantly improved our balance sheet and solidified the foundation for our planned uplisting from the OTC Markets to a national exchange before year’s end. We have an exciting year ahead: we are prepared and ready for the challenge.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and specialty services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food and beverage industries, today updated stakeholders on the company’s key 2022 goals. PBI believes these goals are attainable in the current fiscal year and that their achievement will put the company on a rapid path to sustained growth, value increase and profitability. “In addition to the record number of instrument orders for a month, interest and engagement with our enabling BaroFold Platform protein refolding services has grown significantly over the past few months,” said Richard T. Schumacher, president and CEO of PBI. “We have also made measurable progress thus far in Q1 2022 in preparing for the commercialization of our revolutionary Ultra Shear Technology(TM) (‘UST(TM)’) Platform. Of particular note, we have significantly improved our balance sheet and solidified the foundation for our planned uplisting from the OTC Markets to a national exchange before year’s end. We have an exciting year ahead: we are prepared and ready for the challenge.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
